Testing a new staging system for cutaneous melanoma proposed by the American Joint Committee on Cancer.

[1]  Martin F. Mihm,et al.  A new American Joint Committee on Cancer staging system for cutaneous melanoma , 2000, Cancer.

[2]  A. Benner,et al.  S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. Mansour,et al.  A long-term analysis of 620 patients with malignant melanoma at a major referral center. , 1998, Surgery.

[4]  Q. Dong,et al.  Prognostic factors for survival of patients treated systemically for disseminated melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Garbe,et al.  Prolonged survival of 2 years or longer for patients with disseminated melanoma , 1997, Cancer.

[6]  M. Ross,et al.  Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Olsson,et al.  Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985 , 1997, Cancer.

[8]  M. Ross,et al.  Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Morton,et al.  Prognostic factors in 1,521 melanoma patients with distant metastases. , 1995, Journal of the American College of Surgeons.

[10]  C. Garbe,et al.  Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of clark's level for prognostic classification , 1995, Cancer.

[11]  D. Bajorin,et al.  Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysis , 1993, Cancer.

[12]  H. Drepper,et al.  The prognosis of patients with stage III melanoma prospective long‐term study of 286 patients of the fachklinik hornheide , 1993, Cancer.

[13]  C. Balch,et al.  Cutaneous melanoma: prognosis and treatment results worldwide. , 1992, Seminars in surgical oncology.

[14]  D. Coit,et al.  Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis. , 1991, Annals of surgery.

[15]  R. Elashoff,et al.  Improved Long-term Survival After Lymphadenectomy of Melanoma Metastatic to Regional Nodes , 1991 .

[16]  C. Karakousis,et al.  Tumor thickness and prognosis in clinical stage I malignant melanoma , 1989, Cancer.

[17]  D. Easton,et al.  Prognostic factors related to survival and groin recurrence following therapeutic lymph node dissection for lower limb malignant melanoma , 1987, The British journal of surgery.

[18]  C. Balch,et al.  Head and Neck Melanoma in 534 Clinical Stage I Patients: A Prognostic Factors Analysis and Results of Surgical Treatment , 1984, Annals of surgery.

[19]  C. Balch,et al.  A Comparison of Prognostic Factors and Surgical Results in 1,786 Patients with Localized (Stage I) Melanoma Treated in Alabama, USA, and New South Wales, Australia , 1982, Annals of surgery.

[20]  C. Balch,et al.  A Multifactorial Analysis of Melanoma: III. Prognostic Factors in Melanoma Patients with Lymph Node Metastases (Stage II) , 1981, Annals of surgery.

[21]  W. S. Lazarus-Barlow,et al.  THE NATURAL DURATION OF CANCER , 1924, British medical journal.

[22]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[23]  B. O'Sullivan,et al.  Prognostic Factors in Cancer , 1995, UICC International Union Against Cancer / Union Internationale Contre le Cancer.

[24]  N. Dubin,et al.  Prognosis of patients with pathologic stage II cutaneous malignant melanoma. , 1985, Annals of surgery.

[25]  P. Hermanek,et al.  Malignant Melanoma of Skin , 1995 .